Volume 3, Issue 2, February 2025 ISSN (E): 2938-3765

CLINIC CHARACTERISTICS OF CHRONIC HEPATITIS C WITH STEATOSIS

Shamsiyeva Muattar Axmatovna
Bukhara State Medical Institute named after
Abu Ali ibn Sina Uzbekistan Bukhara, Gijduvon Street 23,
https://orcid.org/0009-0003-1895-3352
shamsiyeva.muattar@bsmi.uz, e-mail: info@bsmi.uz

Abstract
Chronic Hepatitis C (CHC) is a major global health issue, with a substantial number of affected individuals developing hepatic steatosis. This study aims to analyze the clinical characteristics of CHC patients with hepatic steatosis, elucidating its impact on disease progression, liver function, and treatment response. Understanding these characteristics is crucial for optimizing therapeutic strategies and improving patient outcomes.

Keywords: Chronic Hepatitis C, hepatic steatosis, fibrosis, metabolic syndrome, antiviral therapy, hepatocellular carcinoma, genetic predisposition.

INTRODUCTION

Chronic Hepatitis C (CHC) is a progressive liver disease caused by the Hepatitis C virus (HCV) [1-4]. A significant proportion of CHC patients develop hepatic steatosis, which can exacerbate liver damage and impact the efficacy of antiviral therapy[5-7]. The prevalence of steatosis among CHC patients varies, with metabolic factors, viral genotype, and lifestyle playing key roles in its development [8-11].

Hepatic steatosis is observed in 40-80% of CHC patients, with higher prevalence in those infected with HCV genotype 3 [12-16]. The presence of metabolic syndrome, including obesity, insulin resistance, and type 2 diabetes mellitus, further increases the likelihood of steatosis [17-20]. The incidence varies globally, influenced by genetic predisposition, diet, and regional healthcare disparities.

Pathophysiology of Hepatic Steatosis in CHC Hepatic steatosis, characterized by lipid accumulation in hepatocytes, occurs due to metabolic dysregulation and direct viral effects [21-25]. HCV genotype 3 is particularly associated with increased lipid accumulation, while metabolic syndrome-related factors such as insulin resistance and obesity further contribute to steatosis in CHC patients. The virus-induced disruption of lipid metabolism leads to decreased lipid export and increased triglyceride deposition in hepatocytes, worsening liver inflammation and fibrosis progression [26-30].

Clinical Manifestations CHC patients with steatosis often exhibit more severe hepatic fibrosis, elevated liver enzyme levels (ALT, AST), and impaired glucose metabolism [31-36]. The presence of steatosis is linked to faster disease progression and increased risk of cirrhosis. Symptoms may

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

include fatigue, hepatomegaly, and in advanced cases, signs of liver decompensation, such as jaundice, ascites, and hepatic encephalopathy [37-40].

Diagnosis and Assessment Diagnosis of CHC with steatosis involves a combination of serological, biochemical, and imaging studies. Liver biopsy remains the gold standard, but non-invasive methods such as transient elastography (FibroScan) and controlled attenuation parameter (CAP) measurement are widely used. MRI and ultrasonography also play significant roles in detecting hepatic fat accumulation. Blood biomarkers, including ALT, AST, and lipid profiles, assist in evaluating the severity of steatosis [41-43].

Impact on Disease Progression and Treatment Steatosis in CHC patients is associated with accelerated fibrosis progression and a higher likelihood of treatment resistance. The advent of direct-acting antivirals (DAAs) has revolutionized HCV treatment, but patients with significant hepatic steatosis may require additional metabolic interventions. Lifestyle modifications, including weight loss, dietary adjustments, and physical activity, are essential for managing steatosis and enhancing antiviral therapy response. Additionally, steatosis has been linked to an increased risk of hepatocellular carcinoma (HCC), making early diagnosis and intervention crucial.

Management Strategies

1. Antiviral Therapy: DAAs remain the cornerstone of CHC treatment, with high sustained virologic response (SVR) rates.
2. Metabolic Control: Addressing insulin resistance, dyslipidemia, and obesity through pharmacological and non-pharmacological means.
3. Lifestyle Interventions: Dietary modifications (low-fat, low-sugar diet) and regular exercise.
4. Adjunctive Therapies: Use of hepatoprotective agents and potential future therapies targeting lipid metabolism.
5. Regular Monitoring: Periodic liver function tests, imaging, and fibrosis assessment to track disease progression.

Future Directions and Research Needs Further studies are required to explore novel therapeutic targets aimed at reducing hepatic steatosis and improving liver health in CHC patients. Investigations into genetic factors influencing steatosis development and progression may provide personalized treatment strategies. Additionally, longitudinal studies assessing the long-term impact of steatosis resolution on HCV-related outcomes will be valuable.

Conclusion

Chronic Hepatitis C with steatosis presents unique clinical challenges, necessitating a comprehensive approach to management. Understanding the interplay between viral and metabolic factors is essential for improving patient outcomes. Further research is needed to explore targeted therapeutic interventions for this patient population.

References

1.Monto A, Alonzo J, Watson J J. and others steatosis in chronic hepatitis C: obesity, diabetes mellitus and the relative contribution of alcohol. Hepatology 200236729-736.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

2.Westin J, Nordlinder H, Lagging M. and others steatosis accelerates the development of fibrosis over time in patients with hepatitis C virus genotype 3. J Hepatol 200237837-842.

3.Hui JM, Kench J, Farrell G C. and other genotype-specific mechanisms for liver steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 200217873-881

4.Shamsiyeva,M.A.(2024)GEPATIT C DA JIGAR SIRROZINI BAHOLASH USULLARI .AMALIY VA TIBBIYOT FANLARI ILMIY JURNAL,2181-3469

5.Shamsiyeva,M.A.(2024)HOMILADORLIK PAYTIDA QIZAMIQ INFEKSIYASI.AMALIY VA TIBBIYOT FANLARI ILMIY JURNAL,2181-3469.

6. Younoss Z, Papatheodoridis G, Cacoub ?, et al. Comprehensive results of hepatitis C virus infection: a multifaceted chronic disease. J Viral Hepatitis. 2018; 25 (Appendix 3): 6-14.

7. Shamsiyeva,M.A.(2024).ЗАРАЖЕНИЕ КОРЬЮ ПРИ БЕРЕМЕННОСТИ .AMALIY VA TIBBIYOT FANLARI ILMIY JURNAL,2181-3469

8.Ibrokhimovna, M. M. . (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. Journal of Intellectual Property and Human Rights, 3(4), 19–25. Retrieved from http://journals.academiczone.net/index.php/jiphr/article/view/2506

9.Elmurodova A.A. (2023). Viral Hepatitis Delta: An Underestimated Threat. Texas Journal of Medical Science, 26, 1–3. Retrieved from https://zienjournals.com/index.php/tjms/article/view/4610

11.Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibrokhimovna Sanokulova Sitora Avazovna Khadieva Dora Isakovna. (2023). CLINICAL AND LABORATORY FEATURES OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH VIRAL LIVER CIRRHOSIS. Journal of Advanced Zoology, 44(S2), 3744–3750. Retrieved from http://www.jazindia.com/index.php/jaz/article/view/1716

12.Mukhammadieva M.I. (2022). Modern clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis //Texas Journal of Medical Science. – 2022.- P. 86-90

13.Shamsiyeva,M.A.(2024).ПРОГНОСТИЧЕСКАЯ ЗНАЧЕНИЯ НЕИНВАЗИВНЫХ МЕТОДИК ДИАГНОСТИКИ ДЛЯ ОЦЕНКИ ФИБРОЗА ПЕЧЕНИ У БОЛЬНЫХ ХРОНИЧЕСКИМ ГЕПАТИТОМ С .AMALIY VA TIBBIYOT FANLARI ILMIY JURNAL,2181-3469

14.Nabiyeva, Z. . (2023). CLINICAL MANIFESTATIONS OF CHRONIC DISEASES ОРГАНОВ OF THE DIGESTIVE SYSTEM IN CHILDREN. Инновационные исследования в современном мире: теория и практика, 2(15), 27–28. извлечено от https://in-academy.uz/index.php/zdit/article/view/13239

15.Mukhammadieva M.I. (2023). Вирус этиологияли жигар циррози беморларида спонтан бактериал перитонит билан асоратланишнинг профилактикаси ва давосини такомиллаштириш//Oriental Renaissance: Innovative, educational, natural and social sciences. -2023.-P.947-953.

16.Oblokulov A.R., M.I.Mukhammadieva.(2022). Clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis//Academicia Globe: Indersciense Research.-2022.- P. 210-216.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

17.Khadieva Dora Isakovna. (2024). Diagnosis and Prediction of Liver Fibrosis in Chronic Viral Hepatitis C in Hiv-Infected. International Journal of Integrative and Modern Medicine, 2(6), 89–94. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/515

18. Shamsiyeva,M.A.(2024).Measles Infection in Pregnancy .RESEARCH JOURNAL OF TRAUMA AND DISABILITY STUDIES ,2720-6866.

19.Mukhammadieva Musharraf Ibrokhimovna. (2024). TREATMENT OF SPONTANEOUS BACTERIAL PERITONITIS COMPLICATED IN VIRUS ETIOLOGY LIVER CIRRHOSIS. JOURNAL OF EDUCATION, ETHICS AND VALUE, 3(6), 73–80. Retrieved from https://jeev.innovascience.uz/index.php/jeev/article/view/723

20.Sanokulova Sitora Avazovna. (2023). Factors of Development of Hepatorenal Syndrome in Patients with Liver Cirrhosis of Viral Etiology. Texas Journal of Medical Science, 26, 4–9. Retrieved from https://www.zienjournals.com/index.php/tjms/article/view/4611

21.Tukhtaboevna, M. Z. . (2022). ACUTE INTESTINAL INFECTIONS IN CHILDREN, MODERN PRINCIPLES OF CORRECTION AND RESTORATION OF WATER-ELECTROLYTE BALANCE. IJTIMOIY FANLARDA INNOVASIYA ONLAYN ILMIY JURNALI, 101–105. Retrieved from https://sciencebox.uz/index.php/jis/article/view/3249

22. Shamsiyeva,M.A.(2024).Medicines for Humans, Modern Problems of Pharmacotherapy of COVID-19 in Pregnancy Women .RESEARCH JOURNAL OF TRAUMA AND DISABILITY STUDIES ,2720-6866.

23.Jalilova, A.S. (2022). THE SPREAD OF CIRRHOSIS OF THE LIVER BY ETIOLOGICAL FACTORS. Oriental renaissance: Innovative, educational, natural and social sciences, 2 (6), 253-257.\

24. Shamsiyeva,M.A.(2024).Methods of Evaluation of Liver Cirrhosis in Hepatitis C .RESEARCH JOURNAL OF TRAUMA AND DISABILITY STUDIES ,2720-6866.

25.Облокулов, А., & Муҳаммадиева, М. (2022). КЛИНИКО-ЛАБОРАТОРНАЯ ХАРАКТЕРИСТИКА СПОНТАННОГО БАКТЕРИАЛЬНОГО ПЕРИТОНИТА ПРИ ЦИРРОЗЕ ПЕЧЕНИ ВИРУСНОЙ ЭТИОЛОГИИИ. Журнал вестник врача, 1(3), 66–69. извлечено от https://inlibrary.uz/index.php/doctors_herald/article/view/2016

26.Oblokulova Z.I, Oblokulov A.R, & Jalilova A.S. (2022). Diagnostic Significance of Hepatic Fibrosis in Patients with Extrahepatic Chronic Viral Hepatitis C. Central Asian Journal of Medical and Natural Science, 3(3), 438-443. Retrieved from https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/806

27.Aslonova.M.R. (2022). Determination of suicidality against the background of Parasitic Diseases in children // INTERNATIONAL JOURNAL OF PHILOSOPHICAL STUDIES AND SOCIAL SCIENCES. – 2022.- P. 9-12.

28.Jalilova, A. S. (2022). Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 1(1), 41-44.

29.Mukhtarova Sh.A. (2022) Age-related features of clinical manifestations of giardiasis // International journal of medical sciences and clinical research 2022;17-21.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

30.Jalilova A.S. (2022). FEATURES OF CLINICAL MANIFESTATIONS OF CYTOMEGALOVIRUS INFECTION IN CHILDREN. International Journal of Medical Sciences And Clinical Research, 2(09), 12–16. https://doi.org/10.37547/ijmscr/Volume02Issue09-04

31.Raximovich, O. A., Sadilloyevna, J. A., Abdulloyevna, M. S., & Farxodovich , R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294. https://doi.org/10.17605/OSF.IO/9CFP6

32.Жалилова А. С. Дилноза Саётовна Косимова. Клинико–Лабораторная Характеристика Пациентов С Covid-19 И Предиктор Антибактериальной Терапии //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2021. – С. 81-86.

33.Abdulloyevna, M. S. . (2023). Tez-Tez Kasal Bo'lgan Bolalarda O'tkir Respirator Kasalliklarning Klinik-Laboratoriya Xususiyatlari. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 29–34. Retrieved from https://sciencebox.uz/index.php/amaltibbiyot/article/view/8680

34.Muxtorova, S. A. (2022). Clinical and laboratoriya features of acute respiratory disease in frequently ill children. Web of scientist: International scientific research journal, 1026-1030.

35.Mukhtarova, S. H. (2022). A.(2022) AGE-RELATED FEATURES OF CLINICAL MANIFESTATIONS OF GIARDIASIS. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES AND CLINICAL RESEARCH, 17-21.

36.Mukhtorova Shokhida Abdulloevna. (2023). Microbiological Indicators of Patients Infected with SarsCov-2. Texas Journal of Medical Science, 21, 41–45. Retrieved from https://www.zienjournals.com/index.php/tjms/article/view/4116

37.Mukhtorova Shokhida Abdulloevna. (2023). CYTOMEGALOVIRUS INFECTIONS IN CHILDREN WITH PRIMARY AND SECONDARY IMMUNE DEFICIENCIES. Academia Science Repository, 4(06), 23–28. Retrieved from http://academiascience.com/index.php/repo/article/view/832

38. Aslonova.M.R. (2023). VITAMIN DEFICIENCY CASES RESULTING FROM PARASITIC DISEASES // Galaxy International Interdisciplinary Research Journal.-2023.-P. 404-409

39.Mukhtorova Shokhida Abdulloevna. (2023). CHARACTERISTIC FEATURES OF THE COURSE OF CITOMEGALOVIRUS INFECTION IN CHILDREN. Galaxy International Interdisciplinary Research Journal, 11(4), 484–487. Retrieved from https://giirj.com/index.php/giirj/article/view/5150..

40.Raximovich, O. A., Sadilloyevna, J. A., Abdulloyevna, M. S., & Farxodovich , R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294. https://doi.org/10.17605/OSF.IO/9CFP6

41.Ш. А, М. (2023). Профилактика Сезонного Распространения Орви Среди Детей Раннего Возраста. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 22–28. Retrieved from https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8678

42.M. I., M. . (2024). Features of the Clinical Course of Virus-Associated Glomerulonephritis in Children and Adolescents. Research Journal of Trauma and Disability Studies, 3(10), 163–169. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/3676

43.Mukhammadieva M. I. (2024). PREVENTION OF COMPLICATIONS WITH SPONTANEOUS BACTERIAL PERITONITIS WITH LIVER CIRRHOSIS OF VIRAL ETIOLOGY. Web of Medicine: Journal of Medicine, Practice and Nursing, 2(12), 191–197. Retrieved from http://webofjournals.com/index.php/5/article/view/2595.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5